Short Interest in BioRestorative Therapies, Inc. (NASDAQ:BRTX) Declines By 17.4%

BioRestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant decrease in short interest during the month of August. As of August 15th, there was short interest totalling 60,800 shares, a decrease of 17.4% from the July 31st total of 73,600 shares. Based on an average daily volume of 1,630,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 1.2% of the company’s shares are short sold.

BioRestorative Therapies Stock Up 0.6 %

Shares of BioRestorative Therapies stock traded up $0.01 during trading hours on Friday, hitting $1.64. The company’s stock had a trading volume of 13,640 shares, compared to its average volume of 28,496. BioRestorative Therapies has a 12 month low of $1.03 and a 12 month high of $3.67. The stock has a 50 day moving average of $1.68 and a 200 day moving average of $1.49.

BioRestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.06. BioRestorative Therapies had a negative return on equity of 107.65% and a negative net margin of 6,898.28%. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period in the prior year, the company earned ($0.77) earnings per share. As a group, equities analysts predict that BioRestorative Therapies will post -1.83 EPS for the current year.

Institutional Investors Weigh In On BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. StoneX Group Inc. acquired a new position in shares of BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned 0.51% of BioRestorative Therapies at the end of the most recent reporting period. Institutional investors and hedge funds own 69.38% of the company’s stock.

Analyst Ratings Changes

Separately, Roth Mkm increased their price target on BioRestorative Therapies from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.